Literature DB >> 26791067

Discordance Between Apolipoprotein B and LDL-Cholesterol in Young Adults Predicts Coronary Artery Calcification: The CARDIA Study.

John T Wilkins1, Ron C Li2, Allan Sniderman3, Cheeling Chan2, Donald M Lloyd-Jones2.   

Abstract

BACKGROUND: High levels of apolipoprotein B (apoB) have been shown to predict atherosclerotic cardiovascular disease (CVD) in adults even in the context of low levels of low-density lipoprotein cholesterol (LDL-C) or non-high-density lipoprotein cholesterol (non-HDL-C).
OBJECTIVES: This study aimed to quantify the associations between apoB and the discordance between apoB and LDL-C or non-HDL-C in young adults and measured coronary artery calcium (CAC) in midlife.
METHODS: Data were derived from a multicenter cohort study of young adults recruited at ages 18 to 30 years. All participants with complete baseline CVD risk factor data, including apoB and year 25 (Y25) CAC score, were entered into this study. Presence of CAC was defined as having a positive, nonzero Agatston score as determined by computed tomography. Baseline apoB values were divided into tertiles of 4 mutually exclusive concordant/discordant groups, based on median apoB and LDL-C or non-HDL-C.
RESULTS: Analysis included 2,794 participants (mean age: 25 ± 3.6 years; body mass index: 24.5 ± 5 kg/m(2); and 44.4% male). Mean lipid values were as follows: total cholesterol: 177.3 ± 33.1 mg/dl; LDL-C: 109.9 ± 31.1 mg/dl; non-HDL-C: 124.0 ± 33.5 mg/dl; HDL-C: 53 ± 12.8 mg/dl; and apoB: 90.7 ± 24 mg/dl; median triglycerides were 61 mg/dl. Compared with the lowest apoB tertile, higher odds of developing Y25 CAC were seen in the middle (odds ratio [OR]: 1.53) and high (OR: 2.28) tertiles based on traditional risk factor-adjusted models. High apoB and low LDL-C or non-HDL-C discordance was also associated with Y25 CAC in adjusted models (OR: 1.55 and OR: 1.45, respectively).
CONCLUSIONS: These data suggest a dose-response association between apoB in young adults and the presence of midlife CAC independent of baseline traditional CVD risk factors.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  early adult life course; lipid; risk factor

Mesh:

Substances:

Year:  2016        PMID: 26791067      PMCID: PMC6613392          DOI: 10.1016/j.jacc.2015.10.055

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   27.203


  25 in total

1.  Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study.

Authors:  J Jeffrey Carr; Jennifer Clark Nelson; Nathan D Wong; Michael McNitt-Gray; Yadon Arad; David R Jacobs; Stephan Sidney; Diane E Bild; O Dale Williams; Robert C Detrano
Journal:  Radiology       Date:  2005-01       Impact factor: 11.105

Review 2.  Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications.

Authors:  Ira Tabas; Kevin Jon Williams; Jan Borén
Journal:  Circulation       Date:  2007-10-16       Impact factor: 29.690

3.  Effect of aging and obesity on the expression of dyslipidaemia in children from families with familial combined hyperlipidaemia.

Authors:  Ewoud ter Avest; Allan D Sniderman; Sebastian J H Bredie; Albert Wiegman; Anton F H Stalenhoef; Jacqueline de Graaf
Journal:  Clin Sci (Lond)       Date:  2007-01       Impact factor: 6.124

4.  Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study.

Authors:  Naveed Sattar; Ken Williams; Allan D Sniderman; Ralph D'Agostino; Steven M Haffner
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

5.  Major lipids, apolipoproteins, and risk of vascular disease.

Authors:  Emanuele Di Angelantonio; Nadeem Sarwar; Philip Perry; Stephen Kaptoge; Kausik K Ray; Alexander Thompson; Angela M Wood; Sarah Lewington; Naveed Sattar; Chris J Packard; Rory Collins; Simon G Thompson; John Danesh
Journal:  JAMA       Date:  2009-11-11       Impact factor: 56.272

6.  LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management.

Authors:  William C Cromwell; James D Otvos; Michelle J Keyes; Michael J Pencina; Lisa Sullivan; Ramachandran S Vasan; Peter W F Wilson; Ralph B D'Agostino
Journal:  J Clin Lipidol       Date:  2007-12       Impact factor: 4.766

7.  Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women.

Authors:  Samia Mora; James D Otvos; Nader Rifai; Robert S Rosenson; Julie E Buring; Paul M Ridker
Journal:  Circulation       Date:  2009-02-09       Impact factor: 29.690

8.  Early adult risk factor levels and subsequent coronary artery calcification: the CARDIA Study.

Authors:  Catherine M Loria; Kiang Liu; Cora E Lewis; Stephen B Hulley; Stephen Sidney; Pamela J Schreiner; O Dale Williams; Diane E Bild; Robert Detrano
Journal:  J Am Coll Cardiol       Date:  2007-05-04       Impact factor: 24.094

9.  Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.

Authors:  P J Barter; C M Ballantyne; R Carmena; M Castro Cabezas; M John Chapman; P Couture; J de Graaf; P N Durrington; O Faergeman; J Frohlich; C D Furberg; C Gagne; S M Haffner; S E Humphries; I Jungner; R M Krauss; P Kwiterovich; S Marcovina; C J Packard; T A Pearson; K Srinath Reddy; R Rosenson; N Sarrafzadegan; A D Sniderman; A F Stalenhoef; E Stein; P J Talmud; A M Tonkin; G Walldius; K M S Williams
Journal:  J Intern Med       Date:  2006-03       Impact factor: 8.989

10.  The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases.

Authors:  J Danesh; S Erqou; M Walker; S G Thompson; R Tipping; C Ford; S Pressel; G Walldius; I Jungner; A R Folsom; L E Chambless; M Knuiman; P H Whincup; S G Wannamethee; R W Morris; J Willeit; S Kiechl; P Santer; A Mayr; N Wald; S Ebrahim; D A Lawlor; J W G Yarnell; J Gallacher; E Casiglia; V Tikhonoff; P J Nietert; S E Sutherland; D L Bachman; J E Keil; M Cushman; B M Psaty; R P Tracy; A Tybjaerg-Hansen; B G Nordestgaard; R Frikke-Schmidt; S Giampaoli; L Palmieri; S Panico; D Vanuzzo; L Pilotto; L Simons; J McCallum; Y Friedlander; F G R Fowkes; A J Lee; F B Smith; J Taylor; J Guralnik; C Phillips; R Wallace; D Blazer; K T Khaw; J H Jansson; C Donfrancesco; V Salomaa; K Harald; P Jousilahti; E Vartiainen; M Woodward; R B D'Agostino; P A Wolf; R S Vasan; M J Pencina; E M Bladbjerg; T Jorgensen; L Moller; J Jespersen; R Dankner; A Chetrit; F Lubin; A Rosengren; L Wilhelmsen; G Lappas; H Eriksson; C Bjorkelund; P Cremer; D Nagel; R Tilvis; T Strandberg; B Rodriguez; L M Bouter; R J Heine; J M Dekker; G Nijpels; C D A Stehouwer; E Rimm; J Pai; S Sato; H Iso; A Kitamura; H Noda; U Goldbourt; V Salomaa; J T Salonen; K Nyyssönen; T-P Tuomainen; D Deeg; J L Poppelaars; T Meade; J Cooper; B Hedblad; G Berglund; G Engstrom; A Döring; W Koenig; C Meisinger; W Mraz; L Kuller; R Selmer; A Tverdal; W Nystad; R Gillum; M Mussolino; S Hankinson; J Manson; B De Stavola; C Knottenbelt; J A Cooper; K A Bauer; R D Rosenberg; S Sato; Y Naito; I Holme; H Nakagawa; H Miura; P Ducimetiere; X Jouven; C Crespo; M Garcia-Palmieri; P Amouyel; D Arveiler; A Evans; J Ferrieres; H Schulte; G Assmann; J Shepherd; C Packard; N Sattar; B Cantin; B Lamarche; J-P Després; G R Dagenais; E Barrett-Connor; D Wingard; R Bettencourt; V Gudnason; T Aspelund; G Sigurdsson; B Thorsson; M Trevisan; J Witteman; I Kardys; M Breteler; A Hofman; H Tunstall-Pedoe; R Tavendale; G D O Lowe; Y Ben-Shlomo; B V Howard; Y Zhang; L Best; J Umans; A Onat; T W Meade; I Njolstad; E Mathiesen; M L Lochen; T Wilsgaard; J M Gaziano; M Stampfer; P Ridker; H Ulmer; G Diem; H Concin; F Rodeghiero; A Tosetto; E Brunner; M Shipley; J Buring; S M Cobbe; I Ford; M Robertson; Y He; A M Ibanez; E J M Feskens; D Kromhout; R Collins; E Di Angelantonio; S Kaptoge; S Lewington; L Orfei; L Pennells; P Perry; K Ray; N Sarwar; M Scherman; A Thompson; S Watson; F Wensley; I R White; A M Wood
Journal:  Eur J Epidemiol       Date:  2007-09-18       Impact factor: 8.082

View more
  34 in total

1.  [Clinical value of apolipoprotein B versus low-density lipoprotein cholesterol in assessing risks of coronary artery disease].

Authors:  Si Chen; Jin-Zhen Zhao; Jing Hu; Zhi-Gang Guo
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-07-20

2.  HDL efflux capacity, HDL particle size, and high-risk carotid atherosclerosis in a cohort of asymptomatic older adults: the Chicago Healthy Aging Study.

Authors:  R Kannan Mutharasan; C Shad Thaxton; Jarett Berry; Martha L Daviglus; Chun Yuan; Jie Sun; Colby Ayers; Donald M Lloyd-Jones; John T Wilkins
Journal:  J Lipid Res       Date:  2017-01-03       Impact factor: 5.922

3.  Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials.

Authors:  Safi U Khan; Muhammad U Khan; Shahul Valavoor; Muhammad Shahzeb Khan; Victor Okunrintemi; Mamas A Mamas; Thorsten M Leucker; Michael J Blaha; Erin D Michos
Journal:  Eur J Prev Cardiol       Date:  2019-09-02       Impact factor: 7.804

4.  Trajectories of Non-HDL Cholesterol Across Midlife: Implications for Cardiovascular Prevention.

Authors:  Karol M Pencina; George Thanassoulis; John T Wilkins; Ramachandran S Vasan; Ann Marie Navar; Eric D Peterson; Michael J Pencina; Allan D Sniderman
Journal:  J Am Coll Cardiol       Date:  2019-07-09       Impact factor: 24.094

Review 5.  Apolipoproteins in vascular biology and atherosclerotic disease.

Authors:  Anurag Mehta; Michael D Shapiro
Journal:  Nat Rev Cardiol       Date:  2021-10-08       Impact factor: 32.419

Review 6.  The art of cardiovascular risk assessment.

Authors:  Jay Khambhati; Marc Allard-Ratick; Devinder Dhindsa; Suegene Lee; John Chen; Pratik B Sandesara; Wesley O'Neal; Arshed A Quyyumi; Nathan D Wong; Roger S Blumenthal; Laurence S Sperling
Journal:  Clin Cardiol       Date:  2018-05-10       Impact factor: 2.882

7.  Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.

Authors:  Brian A Ference; John J P Kastelein; Henry N Ginsberg; M John Chapman; Stephen J Nicholls; Kausik K Ray; Chris J Packard; Ulrich Laufs; Robert D Brook; Clare Oliver-Williams; Adam S Butterworth; John Danesh; George Davey Smith; Alberico L Catapano; Marc S Sabatine
Journal:  JAMA       Date:  2017-09-12       Impact factor: 56.272

8.  High-throughput multivariable Mendelian randomization analysis prioritizes apolipoprotein B as key lipid risk factor for coronary artery disease.

Authors:  Verena Zuber; Dipender Gill; Mika Ala-Korpela; Claudia Langenberg; Adam Butterworth; Leonardo Bottolo; Stephen Burgess
Journal:  Int J Epidemiol       Date:  2021-07-09       Impact factor: 7.196

9.  Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low-Density Lipoprotein Cholesterol or Non-High-Density Lipoprotein Cholesterol.

Authors:  Allan D Sniderman; Shofiqul Islam; Matthew McQueen; Michael Pencina; Curt D Furberg; George Thanassoulis; Salim Yusuf
Journal:  J Am Heart Assoc       Date:  2016-10-13       Impact factor: 5.501

10.  Apolipoprotein B discordance with low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in relation to coronary artery calcification in the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Jing Cao; Sarah O Nomura; Brian T Steffen; Weihua Guan; Alan T Remaley; Amy B Karger; Pamela Ouyang; Erin D Michos; Michael Y Tsai
Journal:  J Clin Lipidol       Date:  2019-11-29       Impact factor: 4.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.